These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 31316010)

  • 21. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Catch and Release of Cytokines Mediated by Tumor Phosphatidylserine Converts Transient Exposure into Long-Lived Inflammation.
    Oyler-Yaniv J; Oyler-Yaniv A; Shakiba M; Min NK; Chen YH; Cheng SY; Krichevsky O; Altan-Bonnet N; Altan-Bonnet G
    Mol Cell; 2017 Jun; 66(5):635-647.e7. PubMed ID: 28575659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.
    Zemek RM; Chin WL; Nowak AK; Millward MJ; Lake RA; Lesterhuis WJ
    Front Immunol; 2020; 11():223. PubMed ID: 32133005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes.
    Olson KC; Kulling Larkin PM; Signorelli R; Hamele CE; Olson TL; Conaway MR; Feith DJ; Loughran TP
    Cytokine; 2018 Nov; 111():551-562. PubMed ID: 30455079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type I interferon-mediated tumor immunity and its role in immunotherapy.
    Yu R; Zhu B; Chen D
    Cell Mol Life Sci; 2022 Mar; 79(3):191. PubMed ID: 35292881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer.
    Nakayama Y; Mimura K; Tamaki T; Shiraishi K; Kua LF; Koh V; Ohmori M; Kimura A; Inoue S; Okayama H; Suzuki Y; Nakazawa T; Ichikawa D; Kono K
    Int J Oncol; 2019 Jun; 54(6):2030-2038. PubMed ID: 31081058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
    Cao Y; Wang X; Jin T; Tian Y; Dai C; Widarma C; Song R; Xu F
    Signal Transduct Target Ther; 2020 Oct; 5(1):250. PubMed ID: 33122640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors.
    Davis-Marcisak EF; Fitzgerald AA; Kessler MD; Danilova L; Jaffee EM; Zaidi N; Weiner LM; Fertig EJ
    Genome Med; 2021 Aug; 13(1):129. PubMed ID: 34376232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineering nanoparticles to locally activate T cells in the tumor microenvironment.
    Wang D; Wang T; Yu H; Feng B; Zhou L; Zhou F; Hou B; Zhang H; Luo M; Li Y
    Sci Immunol; 2019 Jul; 4(37):. PubMed ID: 31300478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.
    Tabellini G; Vairo D; Scomodon O; Tamassia N; Ferraro RM; Patrizi O; Gasperini S; Soresina A; Giardino G; Pignata C; Lougaris V; Plebani A; Dotta L; Cassatella MA; Parolini S; Badolato R
    J Allergy Clin Immunol; 2017 Aug; 140(2):553-564.e4. PubMed ID: 28069426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
    Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
    J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural Killer Cell-Derived Interferon-Gamma Promotes Hepatocellular Carcinoma Through the Epithelial Cell Adhesion Molecule-Epithelial-to-Mesenchymal Transition Axis in Hepatitis B Virus Transgenic Mice.
    Chen Y; Hao X; Sun R; Wei H; Tian Z
    Hepatology; 2019 Apr; 69(4):1735-1750. PubMed ID: 30329167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct requirements for IFNs and STAT1 in NK cell function.
    Lee CK; Rao DT; Gertner R; Gimeno R; Frey AB; Levy DE
    J Immunol; 2000 Oct; 165(7):3571-7. PubMed ID: 11034357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
    Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
    Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of a protumorigenic IFNγ/STAT1/IRF-1 signaling pathway in keratinocytes following exposure to solar ultraviolet light.
    Blazanin N; Cheng T; Carbajal S; DiGiovanni J
    Mol Carcinog; 2019 Sep; 58(9):1656-1669. PubMed ID: 31237385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling.
    Shi Y; Zheng X; Peng H; Xu C; Sun R; Tian Z; Sun H; Wang X
    Cancer Immunol Res; 2024 Oct; 12(10):1438-1451. PubMed ID: 38990095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation.
    Jing H; Hettich M; Gaedicke S; Firat E; Bartholomä M; Niedermann G
    J Immunother Cancer; 2019 Feb; 7(1):55. PubMed ID: 30808414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.